SMG9 can influence its activity through various biochemical pathways by altering the cellular environment in a way that promotes its activation. Forskolin, a well-known activator of adenylate cyclase, leads to an increase in cyclic AMP (cAMP) levels within the cell. The elevated cAMP can enhance the SMG9-involved mRNA surveillance pathways by influencing the phosphorylation states of associated proteins, which in turn may activate SMG9. IBMX, another chemical in this context, acts as a non-specific inhibitor of phosphodiesterases, thereby preventing the degradation of cAMP. This results in an accumulation of cAMP, which can activate SMG9 through the cAMP-dependent pathways. Similarly, Dibutyryl-cAMP, a cAMP analog, activates cAMP-dependent pathways, possibly leading to the activation of SMG9. Rolipram complements this action by selectively inhibiting phosphodiesterase 4 which also results in increased levels of cAMP, further supporting the activation of SMG9.
cAMP-related mechanisms, other pathways and signaling molecules play a role in the activation of SMG9. Lithium chloride, as a glycogen synthase kinase 3 (GSK-3) inhibitor, may stabilize and activate beta-catenin. This alteration in the cellular signaling milieu could indirectly lead to the activation of SMG9. Similarly, other GSK-3 inhibitors like SB 216763 and BIO can change Wnt signaling, which could result in an environment that supports SMG9 activity. Piceatannol and Okadaic acid, by inhibiting Syk kinase and protein phosphatases 1 and 2A respectively, may alter downstream signaling pathways, thereby enhancing the activity of SMG9. Epigallocatechin gallate, a polyphenol, can influence multiple signaling pathways and might enhance the activity of SMG9 by modulating the phosphorylation patterns of proteins involved in mRNA surveillance. Lastly, MG132, by inhibiting the proteasome, may increase the levels of proteins in SMG9-related pathways, indirectly enhancing its functional activity through stabilization of associated signaling proteins.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, increases cAMP by preventing its degradation, potentially promoting the activity of SMG9 through the cAMP-dependent pathway. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A polyphenol that can influence multiple signaling pathways; it might enhance the activity of SMG9 by altering the phosphorylation patterns of proteins involved in mRNA surveillance. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
A glycogen synthase kinase 3 inhibitor, which could lead to stabilization and activation of beta-catenin, subsequently influencing the cellular contexts in which SMG9 operates. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Inhibits Syk kinase, which could alter downstream signaling pathways, thereby potentially enhancing the activity of proteins like SMG9 in the mRNA surveillance complex. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that may increase the levels of certain proteins that are involved in the same pathways as SMG9, potentially enhancing its functional activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cAMP analog that activates cAMP-dependent pathways, potentially leading to activation of processes in which SMG9 is involved. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
A phosphatase inhibitor that can enhance phosphorylation levels of various proteins, possibly leading to activation of SMG9 through altered signaling dynamics. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A small molecule inhibitor of GSK-3, potentially leading to altered signaling pathways that could enhance the functional activity of SMG9. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
A potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation of proteins in pathways where SMG9 is active, potentially enhancing its activity. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
A GSK-3 inhibitor that could lead to changes in Wnt signaling, possibly resulting in an environment that promotes the activity of SMG9. | ||||||